Active Awards Portfolio Dashboard

It takes a lot of effort to develop a promising stem cell research idea into an effective treatment that can help patients. CIRM funds a pipeline of projects spanning discovery, translation and clinical stage research. Check out our portfolio of active research awards in our interactive dashboard below. For a detailed list of CIRM-funded clinical trials, visit our Clinical Trials Dashboard.

Reset

Disease Cell Type Therapeutic or Technology Institution Stage Project Objective Details
Immune Disease Gene Therapy (All), Gene-modified, donor cell therapy, Therapeutic Approach Tr1X Inc.
Clinical Trial, Phase 1 or Phase 1/2
Autoimmune Disorder, Lupus, Systemic Lupus Erythematosus (SLE) iPS Cell Gene Therapy (All), Gene-modified, donor cell therapy, Therapeutic Approach Fate Therapeutics
Clinical Trial, Phase 1 or Phase 1/2
Blood Cancer, Cancer, Leukemia, Acute Myeloid (AML) Somatic Cell Gene Therapy (All), Gene-modified, donor cell therapy, Therapeutic Approach Senti Bio
Clinical Trial, Phase 1 or Phase 1/2
Blood Disorders, Severe Combined Immunodeficiency, Adenosine deaminase-deficient (ADA-SCID) Adult or Tissue Stem Cell Biologic, Gene modification, Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach UCLA
Clinical Trial, Phase 3
Blood Disorders Somatic Cell Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach Nexcella, Inc.
Clinical Trial, Phase 1 or Phase 1/2
Brain Cancer, Cancer, Solid Tumors Somatic Cell Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach UCSF
Clinical Trial, Phase 1 or Phase 1/2
Neurological Disorders, Parkinson's Disease iPS Cell Personalized cell therapy, Therapeutic Approach Aspen Neuroscience
Clinical Trial, Phase 1 or Phase 1/2
Cancer, Solid Tumors Somatic Cell Gene Therapy (All), Gene-modified, donor cell therapy, Therapeutic Approach Allogene Therapeutics
Clinical Trial, Phase 1 or Phase 1/2
Brain Cancer, Cancer, Solid Tumors Gene Therapy (All), Gene Therapy, cell free, Therapeutic Approach UCSF
Clinical Trial, Phase 1 or Phase 1/2
Age-related macular degeneration, Vision Loss Adult or Tissue Stem Cell Donor cell therapy, Therapeutic Approach Luxa Biotechnology
Clinical Trial, Phase 1 or Phase 1/2
Danon Disease, Metabolic Disorders, Pediatrics Gene Therapy (All), Gene Therapy, cell free, Therapeutic Approach Rocket Pharmaceuticals, Inc.
Clinical Trial, Phase 2
Developmental Disorders, Neurological Disorders, Spina Bifida Adult or Tissue Stem Cell Donor cell therapy, Therapeutic Approach UC Davis
Clinical Trial, Phase 2
Brain Cancer, Cancer, Solid Tumors Adult or Tissue Stem Cell Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach Stanford
Clinical Trial, Phase 1 or Phase 1/2
Blood Cancer, Cancer, Leukemia, Acute Myeloid (AML) Gene Therapy (All), Gene-modified, donor cell therapy, Therapeutic Approach COH
Clinical Trial, Phase 1 or Phase 1/2
Neurological Disorders, Other Gene Therapy (All), Gene Therapy, cell free, Nucleic acid based therapy, Therapeutic Approach UCSD
Clinical Trial, Phase 1 or Phase 1/2
Cancer, Melanoma, Solid Tumors Somatic Cell Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach Stanford
Clinical Trial, Phase 1 or Phase 1/2
Kidney Disease Adult or Tissue Stem Cell Donor cell therapy, Therapeutic Approach UCLA
Clinical Trial, Phase 1 or Phase 1/2
Age-related macular degeneration, Vision Loss Embryonic Stem Cell Donor cell therapy, Therapeutic Approach Regenerative Patch Technologies LLC
Clinical Trial, Phase 2
HIV/AIDS, Infectious Disease Other Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach COH
Clinical Trial, Phase 1 or Phase 1/2
Corneal Damage, Vision Loss Adult or Tissue Stem Cell Biologic, Exosomes based therapy, Therapeutic Approach Combangio
Clinical Trial, Phase 2
Bone or Cartilage Disease, Hearing Loss, Intellectual Disability, Metabolic Disorders, Neurological Disorders, Vision Loss Somatic Cell Personalized cell therapy, Therapeutic Approach Immusoft Corporation
Clinical Trial, Phase 1 or Phase 1/2
Cancer, Solid Tumors Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach Eureka Therapeutics, Inc.
Clinical Trial, Phase 1 or Phase 1/2
Anemia, Blood Disorders Adult or Tissue Stem Cell Antibody, Biologic, Therapeutic Approach Stanford
Clinical Trial, Phase 1 or Phase 1/2
Bone or Cartilage Disease, Osteoarthritis Gene Therapy (All), Gene Therapy, cell free, Therapeutic Approach Genascence Corporation
Clinical Trial, Phase 1 or Phase 1/2
Anemia, Blood Disorders Somatic Cell Cell processing & handling, Immune tolerance/management, Technology COH
Clinical Trial, Phase 1 or Phase 1/2
Anemia, Blood Disorders, Bone Marrow Transplant and Viral Infection Adult or Tissue Stem Cell Immune tolerance/management, Technology Stanford
Clinical Trial, Phase 1 or Phase 1/2
Epilepsy, Neurological Disorders Embryonic Stem Cell Donor cell therapy, Therapeutic Approach Neurona Therapeutics
Clinical Trial, Phase 1 or Phase 1/2
HIV/AIDS, Infectious Disease Gene Therapy (All), Gene Therapy, cell free, Therapeutic Approach Excision BioTherapeutics
Clinical Trial, Phase 1 or Phase 1/2
Muscle Injury, Skeletal/Smooth Muscle disorders Adult or Tissue Stem Cell Personalized cell therapy, Therapeutic Approach UC Davis
Clinical Trial, Phase 1 or Phase 1/2
Brain Cancer, Cancer, Solid Tumors Adult or Tissue Stem Cell Gene Therapy (All), Gene-modified, donor cell therapy, Therapeutic Approach COH
Clinical Trial, Phase 1 or Phase 1/2
Blood Disorders, IPEX Syndrome Adult or Tissue Stem Cell Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach Stanford
Clinical Trial, Phase 1 or Phase 1/2
Cancer, Solid Tumors Adult or Tissue Stem Cell Personalized cell therapy, Therapeutic Approach BioEclipse Therapeutics INC.
Clinical Trial, Phase 1 or Phase 1/2
Brain Cancer, Cancer, Solid Tumors Adult or Tissue Stem Cell Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach Stanford
Clinical Trial, Phase 1 or Phase 1/2
Heart Disease, Heart failure Embryonic Stem Cell Donor cell therapy, Therapeutic Approach Stanford
Clinical Trial, Phase 1 or Phase 1/2
B cell cancers, Blood Cancer, Cancer, Leukemia, Leukemia, Acute Myeloid (AML) Adult or Tissue Stem Cell Donor cell therapy, Therapeutic Approach Stanford
Clinical Trial, Phase 1 or Phase 1/2
Amyotrophic Lateral Sclerosis, Neurological Disorders Adult or Tissue Stem Cell Gene Therapy (All), Gene-modified, donor cell therapy, Therapeutic Approach Cedars-Sinai
Clinical Trial, Phase 1 or Phase 1/2
Neurological Disorders, Stroke Embryonic Stem Cell Donor cell therapy, Therapeutic Approach Stanford
Clinical Trial, Phase 1 or Phase 1/2
Brain Cancer, Cancer, Solid Tumors Adult or Tissue Stem Cell Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach COH
Clinical Trial, Phase 1 or Phase 1/2
HIV/AIDS, Immune Disease, Infectious Disease Adult or Tissue Stem Cell Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach UCSF
Clinical Trial, Phase 1 or Phase 1/2
Neurological Disorders, Parkinson's Disease Vital Research Opportunity Gene Therapy (All), Gene Therapy, cell free, Therapeutic Approach Brain Neurotherapy Bio
Clinical Trial, Phase 1 or Phase 1/2
Corneal Damage, Vision Loss Adult or Tissue Stem Cell Personalized cell therapy, Therapeutic Approach UCLA
Clinical Trial, Phase 1 or Phase 1/2
Retinitis Pigmentosa, Vision Loss Adult or Tissue Stem Cell Donor cell therapy, Therapeutic Approach Cedars-Sinai
Clinical Trial, Phase 1 or Phase 1/2
Brain Cancer, Breast Cancer, Cancer, Solid Tumors Adult or Tissue Stem Cell Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach COH
Clinical Trial, Phase 1 or Phase 1/2
Cystinosis, Kidney Disease, Kidney Failure, Metabolic Disorders Adult or Tissue Stem Cell Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach UCSD
Clinical Trial, Phase 1 or Phase 1/2
Diabetes, Metabolic Disorders, Type 1 diabetes Adult or Tissue Stem Cell Donor cell therapy, Therapeutic Approach UCSF
Clinical Trial, Phase 1 or Phase 1/2
Blood Disorders, Severe Combined Immunodeficiency, X-linked (X-SCID) Adult or Tissue Stem Cell Antibody, Biologic, Therapeutic Approach Jasper Therapeutics, Inc.
Clinical Trial, Phase 1 or Phase 1/2
Kidney Disease, Kidney Failure Adult or Tissue Stem Cell Donor cell therapy, Therapeutic Approach Stanford
Clinical Trial, Phase 1 or Phase 1/2
Kidney Disease, Kidney Failure Adult or Tissue Stem Cell Donor cell therapy, Therapeutic Approach Stanford
Clinical Trial, Phase 1 or Phase 1/2
Blood Disorders, Genetic Disorder, Immune Disease, Pediatrics, Severe Combined Immunodeficiency, Adenosine deaminase-deficient (ADA-SCID) Adult or Tissue Stem Cell Gene Therapy (All), Gene-modified, personalized cell therapy, Therapeutic Approach UCLA
Clinical Trial, Phase 2
Neurological Disorders Gene Therapy (All), Gene Therapy, cell free, Nucleic acid based therapy, Therapeutic Approach Cure Rare Disease
IND
1 2 3 4 5
Displaying 151 – 200 of 229